Humatrope (Somatropin)

Humatrope is indicated for several growth‑related disorders in children and adults where endogenous growth hormone production is insufficient.

• Treatment of growth hormone deficiency in children to promote normal linear growth.
• Treatment of growth hormone deficiency in adults to improve body composition and quality of life.
• Management of Turner syndrome in girls to increase height.
• Management of Prader‑Willi syndrome to support growth and body composition.
• Treatment of growth failure associated with chronic renal insufficiency.
• Treatment of short stature due to SHOX gene deficiency.

• Humatrope contains recombinant somatropin, which mimics endogenous human growth hormone. After subcutaneous injection, somatropin binds to the growth hormone receptor on target cells, activating the JAK2‑STAT5 signaling cascade. This stimulates hepatic production of insulin‑like growth factor‑1 (IGF‑1) and other downstream mediators, leading to anabolic effects on bone, muscle, and adipose tissue, and promoting linear growth and protein synthesis in the body.

Humatrope may cause a range of adverse reactions, most of which are mild and transient, while rare events can be serious.

Common

• Mild pain, redness, or swelling at the injection site
• Transient headache lasting a few hours
• Joint stiffness or muscle aches, especially in the hips or knees
• Peripheral edema, often noticeable in the hands, feet, or ankles
• Elevated blood glucose levels or reduced glucose tolerance, sometimes detected on routine labs
• Nausea or mild gastrointestinal discomfort

Serious

• Intracranial hypertension (pseudotumor cerebri) presenting with headache, visual changes, or papilledema
• Slipped capital femoral epiphysis, a painful displacement of the hip joint in growing children
• Acute pancreatitis, characterized by severe abdominal pain and elevated pancreatic enzymes
• Severe allergic reactions, including anaphylaxis or serum sickness with rash, fever, and joint pain
• Marked increase in intracranial pressure causing visual disturbances, nausea, and vomiting

Before initiating Humatrope therapy, clinicians should evaluate several safety considerations to minimize risks and ensure appropriate use.

• Assess for active malignancy, as growth hormone may accelerate tumor growth.
• Screen for intracranial hypertension or a history of pseudotumor cerebri.
• Evaluate glucose metabolism; patients with diabetes may require closer monitoring.
• Review family history of hereditary disorders such as multiple endocrine neoplasia.
• Monitor for signs of slipped capital femoral epiphysis in growing children.
• Consider potential for fluid retention in patients with cardiac or renal disease.
• Discuss fertility and pregnancy plans; Humatrope is category B and should be used only if benefits outweigh risks.

Humatrope can interact with other medicines or substances that affect its metabolism or the body's response to growth hormone.

Avoid

• Concomitant use of high‑dose glucocorticoids, which may blunt the anabolic effects of growth hormone.
• Simultaneous administration of insulin‑like growth factor‑1 (IGF‑1) therapy, which can increase the risk of hypoglycemia.

Use with caution

• Antidiabetic agents, as Humatrope may worsen glucose control and require dose adjustments.
• Oral estrogen or combined hormonal contraceptives, which can reduce IGF‑1 generation and diminish efficacy.
• Medications that cause fluid retention, such as thiazide diuretics, may exacerbate edema.
• Drugs that affect hepatic metabolism (e.g., CYP3A4 inducers) could alter somatropin clearance.